Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 4/20 | 0.43 |
| ▸ | PPARA | Q07869 | 3/20 | 0.43 |
| ▸ | ACP3 | P15309 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30240014 | 1.00 | CNR2 (0.57) | CNR2LMNAPPARGPPARAACP3 | |
| SCHEMBL4189236 | 0.77 | CNR2 (0.49) | CNR2LMNAPPARGPPARAACP3 | |
| SCHEMBL3175964 | 0.76 | ACP3 (0.42) | CNR2LMNAACP3GAASLC6A4 | |
| SCHEMBL7148448 | 0.75 | PNMT (0.47) | CNR2ACP3P2RX7 | |
| SCHEMBL163013 | 0.75 | PNMT (0.47) | CNR2ACP3P2RX7 | |
| SCHEMBL5698922 | 0.75 | ACP3 (0.45) | CNR2LMNAACP3GAASLC6A4 | |
| SCHEMBL28565247 | 0.74 | PDE2A (0.49) | CNR2LMNAACP3SLC6A4P2RX7 | |
| SCHEMBL7784265 | 0.74 | ACP3 (0.44) | CNR2LMNAACP3GAASLC6A4 | |
| SCHEMBL5724918 | 0.73 | CNR2 (0.49) | CNR2LMNAPPARGPPARAACP3 | |
| SCHEMBL31081588 | 0.71 | ACP3 (0.41) | CNR2ACP3SLC6A4P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3615525-B1 | PYRROLE DERIVATIVES AS PLK1 INHIBITORS | SENTINEL ONCOLOGY LTD (GB) | 2024-12-25 | — | — | EP | disclosed |
| US-11884656-B2 | Pyrrole derivatives as PLK1 inhibitors | SENTINEL ONCOLOGY LIMITED (GB) | 2024-01-30 | — | — | US | disclosed |
| CN-110573503-B | Pyrrole derivatives as PLK1 inhibitors | 圣提内尔肿瘤学有限公司 | 2023-03-17 | — | — | CN | disclosed |
| US-20220135552-A1 | PYRROLE DERIVATIVES AS PLK1 INHIBITORS | SENTINEL ONCOLOGY LIMITED (GB) | 2022-05-05 | — | — | US | disclosed |
| US-20220135552-A1 | PYRROLE DERIVATIVES AS PLK1 INHIBITORS | SENTINEL ONCOLOGY LIMITED (GB) | 2022-05-05 | — | — | US | disclosed |
| US-11208405-B2 | Pyrrole derivatives as PLK1 inhibitors | SENTINEL ONCOLOGY LIMITED (GB) | 2021-12-28 | — | — | US | disclosed |
| US-11208405-B2 | Pyrrole derivatives as PLK1 inhibitors | SENTINEL ONCOLOGY LIMITED (GB) | 2021-12-28 | — | — | US | disclosed |
| US-20200247796-A1 | PYRROLE DERIVATIVES AS PLK1 INHIBITORS | SENTINEL ONCOLOGY LIMITED (GB) | 2020-08-06 | — | — | US | disclosed |
| US-20200247796-A1 | PYRROLE DERIVATIVES AS PLK1 INHIBITORS | SENTINEL ONCOLOGY LIMITED (GB) | 2020-08-06 | — | — | US | disclosed |
| EP-3615525-A1 | PYRROLE DERIVATIVES AS PLK1 INHIBITORS | Sentinel Oncology Limited (GB) | 2020-03-04 | — | — | EP | disclosed |
| CN-110573503-A | pyrrole derivatives as PLK1 inhibitors | 圣提内尔肿瘤学有限公司 | 2019-12-13 | — | — | CN | disclosed |
| WO-2018197714-A1 | PYRROLE DERIVATIVES AS PLK1 INHIBITORS | SENTINEL ONCOLOGY LIMITED (GB) | 2018-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11884656-B2 | Pyrrole derivatives as PLK1 inhibitors | PLK1, CDK1, AURKC | CNR2 1602/4885LMNA 2048/4885PPARG 3378/4885 |
| US-20200247796-A1 | PYRROLE DERIVATIVES AS PLK1 INHIBITORS | PLK1, CDK1, AURKC | CNR2 1501/4885LMNA 2046/4885PPARG 3283/4885 |
| US-20220135552-A1 | PYRROLE DERIVATIVES AS PLK1 INHIBITORS | PLK1, CDK1, AURKC | CNR2 1602/4885LMNA 2048/4885PPARG 3378/4885 |
| US-11208405-B2 | Pyrrole derivatives as PLK1 inhibitors | PLK1, CDK1, AURKC | CNR2 1501/4885LMNA 2046/4885PPARG 3283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.